Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Not yet recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Sarcoma 1

Conditions

Ovarian Neoplasms 2573Uterine Cervical Neoplasms 1693Endometrial Neoplasms 1012Fallopian Tube Neoplasms 730Carcinoma, Ovarian Epithelial 681Breast Neoplasms 676Neoplasms 436Carcinoma, Non-Small-Cell Lung 379Colorectal Neoplasms 372Stomach Neoplasms 302Pancreatic Neoplasms 302Uterine Cervical Dysplasia 273Prostatic Neoplasms 262Lung Neoplasms 250Melanoma 247Neoplasm Metastasis 216Peritoneal Neoplasms 197Carcinoma, Renal Cell 193Sarcoma 190Head and Neck Neoplasms 189Urinary Bladder Neoplasms 187Esophageal Neoplasms 187Recurrence 185Triple Negative Breast Neoplasms 181Uterine Neoplasms 176Vulvar Neoplasms 173Squamous Cell Carcinoma of Head and Neck 168Colonic Neoplasms 162Papillomavirus Infections 153Small Cell Lung Carcinoma 128

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Advanced Endometrial Cancer × Gynecologic × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT04574284 2025-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
170 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT06046274 2024-04-30

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Genmab

Phase 2 Withdrawn
Gynecologic

Advanced Endometrial Cancer

NCT01289041 2019-05-30

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Novartis

Phase 2 Completed
70 enrolled 8 charts
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡